Clinical Trial Update: Assessment of Bone Biomarkers for TKI Response in RCC With Bone Metastases, HRQoL and Comparison of Imaging Techniques

View source ↗

Summary

A terminated clinical trial evaluating bone biomarkers for tyrosine kinase inhibitor response in renal cell carcinoma with bone metastases, including health-rel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Snippet

Sponsor: Spanish Oncology Genito-Urinary Group | Conditions: Renal Cell Carcinoma | Status: TERMINATED